- Race Oncology’s (RAC) preclinical research program has shown the Bisantrene treatment to be an effective chemotherapeutic agent
- To test this, sixteen breast cancer cell lines were screened for their sensitivity to Bisantrene and other common anti-cancer drugs
- Results showed Bisantrene was an effective chemotherapeutic agent across a wide range of genetically distinct breast cancer subtypes
- The treatment was able to kill some cancer subtypes that previously proved resistant to treatments that are currently used
- The company is now planning further studies to expand the range of clinically usable Bisantrene drug combinations
- Race Oncology is in the grey, last trading at $3.73
